01791nas a2200193 4500008004100000245018600041210006900227260001500296300001300311490000700324520110500331653001801436653001701454653001601471100002601487700003001513700001901543856003501562 2018 eng d00aPreliminary of Pharmacokinetics Study of Brown Seaweed (Turbinaria decurrens Bory) Extract in Colon Cancer Model Mice Induced by AOM (Azoxymethane) and DSS (Dextran Sodium Sulphate)0 aPreliminary of Pharmacokinetics Study of Brown Seaweed Turbinari cMarch 2018 a567-570.0 v103 a

Introduction: Colon Cancer is one of leading cancer that causes morbidity and mortality worldwide, causes 774,000 deaths. Fucoxanthin contained brown seaweed Bory) extracts showed cytotoxic activity by and study, including colon cancer. This study aims to examine the absorption profile of fucoxanthin in blood plasma on colon cancer model mice. Methods: Mice were induced by azoxymethane (AOM) and two cycle dextran sulfate sodium (DSS). Mice were given an extract of brown seaweed Bory that contain fucoxanthin. Fucoxanthin content in blood plasma analyzed using mobile phase methanol: acetonitrile by Reversed- Phase High-Performance Liquid Chromatography (RP-HPLC) analysis. Results: The maximum concentration of fucoxanthin in blood was at 4 hours after administration, and the plasma concentration is 2.15 nmol/L, T1/2 6.25 h, and AUC 10.75 nmol/L/h Conclusions: The method was applied successfully in a pharmacokinetic study and the resulting oral brown seaweed bioavailability calculated.

10aBrown seaweed10aColon cancer10aFucoxanthin1 aQurrota’Ayun, Nurul1 aZakaria, Astria, Deviyani1 aBahtiar, Anton uhttp://fulltxt.org/article/525